Rituximab for the treatment of the skin manifestations of dermatomyositis: A report of 3 cases - 12/08/11
Reprint requests: Professor H. Miles Prince, Head, Hematology Service, Peter MacCallum Cancer Centre, Locked Bag 1, A’Beckett St, Melbourne, 8006, Victoria, Australia.Melbourne, Malvern, East Melbourne, and Parkville, Australia
Abstract |
Three patients suffering from classic dermatomyositis (juvenile and adult-onset) with prominent recalcitrant skin manifestations are described. All patients demonstrated good control of muscle symptoms on immunosuppressive medications, but their cutaneous disease persisted despite treatment with at least 4 different systemic treatments and topical agents. They were given rituximab, a monoclonal anti-CD20 antibody, achieving a response with minimal side effects. We document our experience with this medication for the cutaneous lesions of dermatomyositis.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. Conflicts of interest: None identified. |
Vol 56 - N° 1
P. 148-153 - janvier 2007 Retour au numéro
Article précédent
- December Iotaderma (#155)
- Robert I. Rudolph
- Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies
- Deborah L. Cummins, Daniel Mimouni, Julia Tzu, Nicole Owens, Grant J. Anhalt, Jon H. Meyerle
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?